色播亚洲精品网站亚洲第一,免费特级黄毛片,北条麻妃久久99精品,最近最新的日本中文字幕,国产精品猎奇系列在线观看,亚洲视频一区二区三区,一级做a毛片在线看

資訊|論壇|病例

搜索

首頁 醫(yī)學(xué)論壇 專業(yè)文章 醫(yī)學(xué)進(jìn)展 簽約作者 病例中心 快問診所 愛醫(yī)培訓(xùn) 醫(yī)學(xué)考試 在線題庫 醫(yī)學(xué)會議

您所在的位置:首頁 > 心血管內(nèi)科診療指南 > 2011STS/SCA更新心臟外科血液保護(hù)臨床指南

2011STS/SCA更新心臟外科血液保護(hù)臨床指南

2014-06-06 16:00 閱讀:7065 來源:愛愛醫(yī) 責(zé)任編輯:張子玲
[導(dǎo)讀] Background. Practice guidelines reflect published liter-ature. Because of the ever changing literature base, it isnecessary to update and revise guideline recommenda-tions from time to time. The Society of Thoracic Surgeonsrecommends review

    《2011STS/SCA更新心臟外科血液保護(hù)臨床指南》內(nèi)容簡介:

    Background. Practice guidelines reflect published liter-ature. Because of the ever changing literature base, it isnecessary to update and revise guideline recommenda-tions from time to time. The Society of Thoracic Surgeonsrecommends review and possible update of previouslypublished guidelines at least every three years. Thissummary is an update of the blood conservation guide-line published in 2007.

    《2011STS/SCA更新心臟外科血液保護(hù)臨床指南》內(nèi)容預(yù)覽:

 
   Routine addition of P2Y12 inhibitors to aspirin therapy early after coronary artery bypass graft (CABG) mayincrease the risk of reexploration and subsequent operation and is not indicated based on availableevidence except in those patients who satisfy criteria for ACC/AHA guideline-recommended dualantiplatelet therapy (eg, patients presenting with acute coronary syndromes or those receiving recentdrug eluting coronary stents)。

    III (B)

    It is reasonable to use preoperative ** (EPO) plus iron, given several days before cardiacoperation, to increase red cell mass in patients with preoperative anemia, in candidates for operation whorefuse transfusion (eg, Jehovah's Witness), or in patients who are at high risk for postoperative anemia.However, chronic use of EPO is associated with thrombotic cardiovascular events in renal failure patientssuggesting caution for this therapy in individuals at risk for such events (eg, coronary revascularizationpatients with unstable symptoms)。

    IIa (B)

    Recombinant human ** (EPO) may be considered to restore red blood cell volume in patientsalso undergoing autologous preoperative blood donation before cardiac procedures. However, no large-scale safety studies for use of this agent in cardiac surgical patients are available, and must be balancedwith the potential risk of thrombotic cardiovascular events (eg, coronary revascularization patients withunstable symptoms)。

    點(diǎn)擊下載***:《2011STS/SCA更新心臟外科血液保護(hù)臨床指南》


分享到:
  版權(quán)聲明:

  本站所注明來源為"愛愛醫(yī)"的文章,版權(quán)歸作者與本站共同所有,非經(jīng)授權(quán)不得轉(zhuǎn)載。

  本站所有轉(zhuǎn)載文章系出于傳遞更多信息之目的,且明確注明來源和作者,不希望被轉(zhuǎn)載的媒體或個人可與我們

  聯(lián)系zlzs@120.net,我們將立即進(jìn)行刪除處理

意見反饋 關(guān)于我們 隱私保護(hù) 版權(quán)聲明 友情鏈接 聯(lián)系我們

Copyright 2002-2024 Iiyi.Com All Rights Reserved